72
Participants
Start Date
July 24, 2012
Primary Completion Date
January 29, 2015
Study Completion Date
March 13, 2018
Azacitidine
Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
Peking University People's Hospital, Beijing
Ruijin Hospital Shanghai Jiaotong University, Shanghai
Shanghai 6th Hospital, Shanghai
The 1st Hospital of Soochow University, Suzhou
Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin
The 301 Hospital- Chinese PLA General Hospital, Beijing
1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou
Wuhan Union Hospital, Wuhan
Guangdong General Hospital, Guangzhou
West China Hospital of Sichuan University, Chengdu
The Third Hospital of Peking University, Beijing
Lead Sponsor
Celgene
INDUSTRY